Humana Inc. (NYSE:HUM) is a leading health and well-being company in the United States, offering a broad spectrum of health insurance products and services, with a focus on government-sponsored programs like Medicare. Competing against giants such as UnitedHealth Group and Anthem, Humana has recently been rated as "Underperform" by Morgan Stanley, which has also adjusted its price target for the company.
On December 18, 2025, Morgan Stanley announced its decision to hold Humana's stock, which was priced at $260.28. The firm also lowered Humana's price target from $277 to $262, as reported by TheFly. Despite this, Humana's stock price has shown resilience, reflecting an increase of $2.12 or 0.82% to reach $260.28.
The U.S. Defense Department's decision to award Humana a $7.3 billion contract for health care and administrative support services underscores the company's strong relationship with the Pentagon. This substantial deal highlights Humana's role in delivering essential services to the U.S. military, which could positively impact its future financial performance.
Humana's stock has experienced fluctuations, with a trading range between $256.35 and $266.08 during the day. Over the past year, the stock has seen a high of $315.35 and a low of $206.87. The company's market capitalization stands at approximately $31.3 billion, indicating its significant presence in the health insurance industry.
Today's trading volume for Humana is 1,073,203 shares, reflecting investor interest in the stock. Despite Morgan Stanley's "Underperform" rating, Humana's recent contract with the U.S. Defense Department may provide a positive outlook for the company's future growth and stability.
